Eli Lilly and Sigilon Therapeutics have announced a partnership that looks to break new ground in the management of type 1 diabetes, by using stem cells to provide a long-term treatment solution.
 

Ionis Pharmaceuticals Inc said on Monday a licensing deal for its fatty liver disease treatment with AstraZeneca Plc could fetch up to $300 million in milestone payments.

Merck & Co said a late-stage trial of its blockbuster cancer drug Keytruda met the main goal in helping previously untreated lung cancer patients live longer, sending its shares up 2.6 percent in premarket trade.

Partners Biogen and Samsung Bioepis have secured the future of their Humira (adalimumab) biosimilar after penning a deal with Abbvie which grants patent licenses for the sale of the product in Europe and the US, and...

Roche’s multiple sclerosis drug, Ocrevus (ocrelizumab), has been a big new growth driver for the company, especially in the US, as it managed to bring in $902 million in sales during the 2017 financial year.
 

Takeda’s surprise announcement that it was weighing up a move for Shire had some analysts sceptical about whether the Japanese company could pull off such a larger acquisition.
 

Bad news for Johnson & Johnson as it emerges that the US pharma giant has been ordered to pay out $37 million in damages after losing the first trial in a legal dispute which alleges that its Baby Powder product...

After Eli Lilly’s Cyramza flopped a phase 3 liver cancer trial in 2014, the company went back to the drawing board to design a trial for a specific subpopulation. Nearly four years later, it’s back with a win.

28 years after the US first pioneered proton beam therapy at Loma Linda University Medical Center, the UK now has its own centre that will be able to provide this type of treatment to patients.

Dit artikel is onderdeel van de serie over GDPR en het effect op digital marketing. In deze editie zoom ik in op de effecten op (programmatic) display advertising. Omdat hier al heel veel over is gepubliceerd, zoeken we...

A study conducted by researchers at UT Southwestern’s Simmons Cancer Center has revealed that a combination of two specific drug varieties may offer an effective treatment for most kinds of lung cancer by blocking their...

Zorgverzekeraar VGZ is gestopt met het beleggen in farmaceutische bedrijven die extreem hoge prijzen vragen voor medicijnen. VGZ stopte daarmee nadat het Zorginstituut die handelwijze van farmaceuten niet-ethisch heeft...

UK drug watchdog NCIE has issued draft guidance rejecting the routine use of Sanofi’s Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis on the NHS in adults when systemic therapy is...

A surprise new name was thrown into the ring to take on Pfizer’s healthcare unit but speculation suggests that valuation is once again the sticking point, indicating that Pfizer may not be able to find anyone willing to...

Takeda is considering making a bold move for Shire, after announcing, as per UK regulations, that it may make an approach for the company.
 

Teva has been spared a sizeable payout to GlaxoSmithKline after a federal judge overturned a US jury verdict demanding that the Israeli firm hand over $235 million in damages related to infringement of one of the...

The discovery of an entirely new organ, the 80th to be discovered in the human body, could have serious implications for our collective understanding of cancer and a number of other diseases.
 

Ablynx has revealed that its interleukin 6 pathway via its IL-6 receptor (IL-6R) vobarilizumab failed to meet its primary endpoint in a Phase 2 trial, presenting implications for Sanofi who will acquire the drug...